Trial Profile
A Retrospective, Single-Center, Real-World Study Investigating Clinical Survival of Subsequent Therapy in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients with Crizotinib Resistance
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Sep 2018 Results (n=150 ALK positive NSCLC patients who had acquired crizotinib resistance from Aug 2011 to May 2017) presented at the 19th World Conference on Lung Cancer
- 18 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.